专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

71. 发明专利

CA2877746A1 OPTIMIZATION OF ANTIBODIES THAT BIND LYMPHOCYTE ACTIVATION GENE-3 (LAG-3), AND USES THEREOF 未知
公开(公告)号：CA2877746A1
公开(公告)日：2014-01-09
申请号：CA2877746
申请日：2013-07-02
申请人： SQUIBB BRISTOL MYERS CO
发明人： LONBERG NILS , SRINIVASAN MOHAN
IPC分类号： C07K16/28
摘要： The present invention provides isolated monoclonal antibodies that specifically bind LAG-3, and have optimized functional properties compared to previously described anti-LAG-3 antibodies, such as antibody 25F7 (US 2011/0150892 A1). These properties include reduced deamidation sites, while still retaining high affinity binding to human LAG-3, and physical (i.e., thermal and chemical) stability. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided, as well as immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies. The present invention also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which the antibodies are co-administered with at least one additional immunostimulatory antibody, is also provided.

72. 发明专利

EA039219B1 АНТИТЕЛА К TIGIT 未知
公开(公告)号：EA039219B1
公开(公告)日：2021-12-20
申请号：EA201791171
申请日：2015-12-22
申请人： SQUIBB BRISTOL MYERS CO
发明人： MAURER MARK F , CHEN TSENG-HUI TIMOTHY , DEVAUX BRIGITTE , SRINIVASAN MOHAN , JULIEN SUSAN H , SHEPPARD PAUL O , ARDOUREL DANIEL F , CHAKRABORTY INDRANI
摘要： Визобретениипредусмотреныантителаилиихантигенсвязывающиефрагменты, которыесвязываютсяс человеческим TIGIT (Т-клеточнымиммунорецепторомс доменами Ig и ITIM), атакжеиспользованиеэтихантителилифрагментовв терапевтическихприменениях, такихкаклечениезлокачественнойопухолиилихроническойвируснойинфекции. Такойспособлеченияпредусматриваеткомбинированнуютерапиюс ингибиторамидругихиммуномодулирующихрецепторныхвзаимодействий, такихкаквзаимодействие PD-1/PD-L1. Крометого, визобретениидополнительнопредусмотреныполинуклеотиды, кодирующиевариабельнуюобластьтяжелойи/илилегкойцепейантител, векторыэкспрессии, содержащиеполинуклеотиды, кодирующиевариабельнуюобластьтяжелойи/илилегкойцепиантител, клетки, содержащиевекторы, испособыполученияантителилифрагментовпосредствомэкспрессииихизклеток.

73. 发明专利

PE20210665A1 ANTICUERPOS CONTRA MICA Y/O MICB Y SUS USOS 未知
公开(公告)号：PE20210665A1
公开(公告)日：2021-03-31
申请号：PE2020001441
申请日：2019-03-22
申请人： SQUIBB BRISTOL MYERS CO
发明人： KUHNE MICHELLE RENEE , KORMAN ALAN J , HUANG HAICHUN , YIN YIMING , GRAZIANO ROBERT F , BEZMAN NATALIE A , STROP PAVEL , HUANG RICHARD Y , CHEN GUODONG , SRINIVASAN MOHAN , LEE PETER SUNG KEUN , CAMDERE GAMZE OZLEM
IPC分类号： C07K16/28 , A61P35/00
摘要： La presente invencion se refiere a anticuerpos que se unen de manera especifica a la secuencia A relacionada con el polipeptido de MHC de clase I humano (MICA) y/o la secuencia B relacionada con el polipeptido de MHC de clase I humano (MICB), que comprenden una VH-CDR3 seleccionada del grupo que consiste en SEQ ID NO: 7, 17, 27, 37 y 47; una VH-CDR2 seleccionada del grupo que consiste en SEQ ID NO: 6, 16, 26, 36 y 46; una VH-CDR1 seleccionada del grupo que consiste en SEQ ID NO: 5, 15, 25, 35 y 45; una VL-CDR1 seleccionada del grupo que consiste en SEQ ID NO: 8, 18, 28, 38 y 48; una VL-CDR2 seleccionada del grupo que consiste en SEQ ID NO: 9, 19, 29, 39 y 49; y una VL-CDR3 seleccionada del grupo que consiste en SEQ ID NO: 10, 20, 30, 40 y 50. Comprende tambien polinucleotidos, vectores, una celula huesped, un inmunoconjugado, una composicion farmaceutica y un metodo para tratar un tipo de cancer

75. 发明专利

MA40662B1 Anticorps contre tigit 未知
公开(公告)号：MA40662B1
公开(公告)日：2020-12-31
申请号：MA40662
申请日：2015-12-22
申请人： SQUIBB BRISTOL MYERS CO
发明人： SRINIVASAN MOHAN , CHAKRABORTY INDRANI , MAURER MARK F , CHEN TSENG-HUI TIMOTHY , DEVAUX BRIGITTE , JULIEN SUSAN H , SHEPPARD PAUL O , ARDOUREL DANIEL F
IPC分类号： C07K16/28
摘要： La présente invention concerne des anticorps, ou des fragments liant l'antigène de ceux-ci, qui se lient à un tigit (immunorécepteur de cellule t avec des domaines d'ig et d'itim) humain, ainsi que des utilisations de ces anticorps ou fragments dans des applications thérapeutiques, par exemple dans le traitement du cancer ou d'une infection virale chronique. Ce procédé de traitement comprend un traitement combiné avec des inhibiteurs d'autres interactions avec des récepteurs immunomodulateurs, comme une i

76. 发明专利

SI3275899T1 Optimizacija protiteles ki vežejo GEN-3 za aktivacijo limfocitov (LAG-3) in uporaba le-teh 未知
公开(公告)号：SI3275899T1
公开(公告)日：2020-11-30
申请号：SI201331797
申请日：2013-07-02
申请人： SQUIBB BRISTOL MYERS CO
发明人： LONBERG NILS , SRINIVASAN MOHAN
IPC分类号： C07K16/00

77. 发明专利

SI3221346T1 Protitelesa vsebujoča modificirana težko konstantna območja 未知
公开(公告)号：SI3221346T1
公开(公告)日：2020-11-30
申请号：SI201531375
申请日：2015-11-19
申请人： SQUIBB BRISTOL MYERS CO
发明人： LONBERG NILS , KORMAN ALAN J , SELBY MARK J , BARNHART BRYAN C , YAMNIUK AARON P , SRINIVASAN MOHAN , HENNING KARLA A , HAN MICHELLE MINHUA , LEI MING , SCHWEIZER LIANG , HATCHER SANDRA V , RAJPAL ARVIND
IPC分类号： C07K16/00

78. 发明专利

LT3221346T ANTIKŪNAI, APIMANTYS MODIFIKUOTAS SUNKIOSIOS GRANDINĖS PASTOVIĄSIAS SRITIS 未知
公开(公告)号：LT3221346T
公开(公告)日：2020-11-10
申请号：LT15804282
申请日：2015-11-19
申请人： SQUIBB BRISTOL MYERS CO
发明人： LONBERG NILS , KORMAN ALAN J , SELBY MARK J , BARNHART BRYAN C , YAMNIUK AARON P , SRINIVASAN MOHAN , HENNING KARLA A , HAN MICHELLE MINHUA , LEI MING , SCHWEIZER LIANG , HATCHER SANDRA V , RAJPAL ARVIND
IPC分类号： C07K16/00 , C07K16/28

80. 发明专利

SG10201913004UA ANTIBODIES AGAINST CD73 AND USES THEREOF 未知
公开(公告)号：SG10201913004UA
公开(公告)日：2020-03-30
申请号：SG10201913004U
申请日：2015-11-19
申请人： SQUIBB BRISTOL MYERS CO
发明人： LONBERG NILS , KORMAN ALAN , BARNHART BRYAN C , YAMNIUK AARON , SRINIVASAN MOHAN , HENNING KARLA A , LEI MING , SEGA EMANUELA , GOODENOUGH ANGELA , JURE-KUNKEL MARIA , CHEN GUODONG , SACK JOHN , HUANG RICHARD , CORBETT MARTIN , MYERS JOSEPH , SCHWEIZER LIANG , HATCHER SANDRA , HUANG HAICHUN , ZHANG PINGPING
摘要： The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式